Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study - Glund, S; Stangier, J; van Ryn, J (Clin Pharmacokinet, 2017)
, et al.